Improved mitochondrial function in brain aging and Alzheimer disease - the new mechanism of action of the old metabolic enhancer piracetam

Frontiers in Neuroscience

Volumn 4, Issue SEP, 2010, Pages

  Leuner, Kristina ^a   Kurz, Christopher ^a   Guidetti, Giorgio ^b   Orgogozo, Jean Marc ^c   Müller, Walter E ^a  

^a GOETHE UNIVERSITY   (Germany)

^b AUSL Modena   (Italy)

^c University Hospital   (France)

Author keywords

Aging; Alzheimer's disease; Mitochondrial dysfunction; Oxidative stress; Piracetam

Indexed keywords

EID: 84875460234     PISSN: 16624548     EISSN: 1662453X     Source Type: Journal    
DOI: 10.3389/fnins.2010.00044     Document Type: Review

References (104)

1. Abdel-Kader, R., Hauptmann, S., Keil, U., Scherping, I., Leuner, K., Eckert, A., and Muller, W. E. (2007). Stabilization of mitochondrial function by Ginkgo biloba extract (EGb 761). Pharmacol. Res. 56, 493-502.
2. Ackerman, P. T., Dykman, R. A., Holloway, C., Paal, N. P., and Gocio, M. Y. (1991). A trial of piracetam in 2 subgroups of students with dyslexia enrolled in summer tutoring. J. Learn Disabil. 24, 542-549.
3. Aleardi, A. M., Benard, G., Augereau, O., Malgat, M., Talbot, J. C., Mazat, J. P., Letellier, T., Dachary-Prigent, J., Solaini, G. C., and Rossignol, R. (2005). Gradual alteration of mitochondrial structure and function by beta-amyloids: importance of membrane viscosity changes, energy deprivation, reactive oxygen species production, and cytochrome c release. J. Bioenerg. Biomembr. 37, 207-225.
4. Anandatheerthavarada, H. K., and Devi, L. (2007). Amyloid precursor protein and mitochondrial dysfunction in Alzheimer's disease. Neuroscientist 13, 626-638.
5. Atamna, H. (2004). Heme, iron, and the mitochondrial decay of ageing. Ageing Res. Rev. 3, 303-318.
6. Atamna, H., Nguyen, A., Schultz, C., Boyle, K., Newberry, J., Kato, H., and Ames, B. N. (2008). Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J. 22, 703-712.
7. Bachurin, S. O., Shevtsova, E. P., Kireeva, E. G., Oxenkrug, G. F., and Sablin, S. O. (2003). Mitochondria as a target for neurotoxins and neuroprotective agents. Neuroprotective Agents 993, 334-344.
8. Balaban, R. S., Nemoto, S., and Finkel, T. (2005). Mitochondria, oxidants, and aging. Cell 120, 483-495.
9. Bastianetto, S., and Quirion, R. (2004). Natural antioxidants and neurodegenerative diseases. Front. Biosci. 9, 3447-3452.
10. Bernales, S., Wagner, S., Protter, A. A., and Hung, D. T. (2008). Dimebon induces neuritic outgrowth and mitochondrial stabilization. Annual Meeting of the Society for Neuroscience, Washington D.C. [543.29/S12].
11. Blanchard, V., Moussaoui, S., Czech, C., Touchet, N., Bonici, B., Planche, M., Canton, T., Jedidi, I., Gohin, M., Wirths, O., Bayer, T. A., Langui, D., Duyckaerts, C., Tremp, G., and Pradier, L. (2003). Time sequence of maturation of dystrophic neurites associated with A beta deposits in APP/PS1 transgenic mice. Exp. Neurol. 184, 247-263.
12. Blasko, I., Kemmler, G., Krampla, W., Jungwirth, S., Wichart, I., Jellinger, K., Tragl, K. H., and Fischer, P. (2005). Plasma amyloid beta protein 42 in non-demented persons aged 75 years: Effects of concomitant medication and medial temporal lobe atrophy. Neurobiol. Aging 26, 1135-1143.
13. Brandao, F., CadeteLeite, A., Andrade, J. P., Madeira, M. D., and PaulaBarbosa, M. M. (1996). Piracetam promotes mossy fiber synaptic reorganization in rats withdrawn from alcohol. Alcohol 13, 239-249.
14. Brandao, F., PaulaBarbosa, M. M., and CadeteLeite, A. (1995). Piracetam impedes hippocampal neuronal loss during withdrawal after chronic alcohol intake. Alcohol 12, 279-288.
15. Callaway, N. L., Riha, P. D., Bruchey, A. K., Munshi, Z., and Gonzalez-Lima, F. (2004). Methylene blue improves brain oxidative metabolism and memory retention in rats. Pharmacol. Biochem. Behav. 77, 175-181.
16. Callaway, N. L., Riha, P. D., Wrubel, K. M., McCollum, D., and Gonzalez-Lima, F. (2002). Methylene blue restores spatial memory retention impaired by an inhibitor of cytochrome oxidase in rats. Neurosci. Lett. 332, 83-86.
17. Cao, J., Liu, Y., Jia, L., Zhou, H. M., Kong, Y., Yang, G., Jiang, L. P., Li, Q. J., and Zhong, L. F. (2007). Curcurnin induces apoptosis through mitochondrial hyperpolarization and mtDNA damage in human hepatoma G2 cells. Free Radic. Biol. Med. 43, 968-975.
18. Christen, Y., and Maixent, J. M. (2002). What is Ginkgo biloba extract EGb 761? An overview - From molecular biology to clinical medicine. Cell. Mol. Biol. 48, 601-611.
19. Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., and Ashe, K. H. (2005). Natural oligomers of the amyloid-protein specifically disrupt cognitive function. Nat. Neurosci. 8, 79-84.
20. Cohen, S. A., and Muller, W. E. (1993). Effects of piracetam on N-methyl-D-aspartate receptor properties in the aged mouse-brain. Pharmacology 47, 217-222.
21. Colell, A., Garcia-Ruiz, C., Mari, M., and Fernandez-Checa, J. C. (2004). Mitochondrial permeability transition induced by reactive oxygen species is independent of cholesterol-regulated membrane fluidity. FEBS Lett. 560, 63-68.
22. Coq, J. O., and Xerri, C. (1999). Acute reorganization of the forepaw representation in the rat SI cortex after focal cortical injury: neuroprotective effects of piracetam treatment. Eur. J. Neurosci. 11, 2597-2608.
23. Croisile, B., Trillet, M., Fondarai, J., Laurent, B., Mauguiere, F., and Billardon, M. (1993). Long-term and high-dose piracetam treatment of Alzheimers-disease. Neurology 43, 301-305.
24. Demay, F., and Bande, J. (1980). Effect of piracetam on volunteers in a low-pressure tank. J. Int. Med. Res. 8, 90-94.
25. Dieterich, M., and Brandt, T. (2010). Imaging cortical activity after vestibular lesions. Restor. Neurol. Neurosci. 28, 47-56.
26. Domanska-Janik, K., and Zaleska, M. (1977). The action of piracetam on 14C-glucose metabolism in normal, and posthypoxic rat cerebral coretx slices. Pol. J. Pharmacol. Pharm. 29, 111-116.
27. Doody, R. S., Gavrilova, S. I., Sano, M., Thomas, R. G., Aisen, P. S., Bachurin, S. O., Seely, L., and Hung, D. (2008). Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372, 207-215.
28. Dormehl, I. C., Jordaan, B., Oliver, D. W., and Croft, S. (1999). SPECT monitoring of improved cerebral blood flow during long-term treatment of elderly patients with nootropic drugs. Clin. Nucl. Med. 24, 29-34.
29. Eckert, A., Hauptmann, S., Scherping, I., Meinhardt, J., Rhein, V., Drose, S., Brandt, U., Fandrich, M., Muller, W. E., and Gotz, J. (2008). Oligomeric and fibrillar species of beta-amyloid (A beta 42) both impair mitochondrial function in P301L tau transgenic mice. J. Mol. Med. 86, 1255-1267.
30. Eckert, G. P., Cairns, N. J., and Muller, W. E. (1999). Piracetam reverses hippocampal membrane alterations in Alzheimer's disease - short communication. J. Neural Transm. 106, 757-761.
31. Evans, N. A., Facci, L., Owen, D. E., Soden, P. E., Burbidge, S. A., Prinjha, R. K., Richardson, J. C., and Skaper, S. D. (2008). A beta(1-42) reduces synapse number and inhibits neurite outgrowth in primary cortical and hippocampal neurons: a quantitative analysis. J. Neurosci. Methods 175, 96-103.
32. Farlow, M. R., Miller, M. L., and Pejovic, V. (2008). Treatment options in Alzheimer's disease: Maximizing benefit, managing expectations. Dement. Geriatr. Cogn. Disord. 25, 408-422.
33. Floyd, R. A., and Hensley, K. (2002). Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol. Aging 23, 795-807.
34. Giurgea, C. E. (1982). The nootropic concept and its prospective implications. Drug Dev. Res. 2, 441-446.
35. Guglielmotto, M., Aragno, M., Autelli, R., Giliberto, L., Novo, E., Colombatto, S., Danni, O., Parola, M., Smith, M. A., Perry, G., Tamagno, E., and Tabaton, M. (2009). The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1 alpha. J. Neurochem. 108, 1045-1056.
36. Gura, T. (2008). Hope in Alzheimer's fight emerges from unexpected places. Nat. Med. 14, 894.
37. Haass, C., and Selkoe, D. J. (2007). Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8, 101-112.
38. Hanna, M. G., and Bhatia, K. P. (1997). Movement disorders and mitochondrial dysfunction. Curr. Opin. Neurol. 10, 351-356.
39. Hauptmann, S., Keil, U., Scherping, I., Bonert, A., Eckert, A., and Muller, W. E. (2006). Mitochondrial dysfunction in sporadic and genetic Alzheimer's disease. Exp. Gerontol. 41, 668-673.
40. Hauptmann, S., Scherping, I., Drose, S., Brandt, U., Schulz, K. L., Jendrach, M., Leuner, K., Eckert, A., and Muller, W. E. (2009). Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol. Aging 30, 1574-1586.
41. He, Z., Liao, Y., Zheng, M., Zeng, F. D., and Guo, L. J. (2008). Piracetam improves cognitive deficits caused by chronic cerebral hypoperfusion in rats. Cell. Mol. Neurobiol. 28, 613-627.
42. Heiss, W. D., Hebold, I., Klinkhammer, P., Ziffling, P., Szelies, B., Pawlik, G., and Herholz, K. (1988). Effect of piracetam on cerebral glucose-metabolism in Alzheimers-disease as measured by positron emission tomography. J. Cereb. Blood Flow Metab. 8, 613-617.
43. Hirata, K., Yamaguchi, H., Takamura, Y., Takagi, A., Fukushima, T., Iwakami, N., Saitoh, A., Nakagawa, M., and Yamada, T. (2005). A novel neurotrophic agent, T-817MA [1-{3-[2-(1-benzothiophen-5-yl) ethoxy] propyl}-3-azetidinol maleate], attenuates amyloid-beta-induced neurotoxicity and promotes neurite outgrowth in rat cultured central nervous system neurons. J. Pharmacol. Exp. Ther. 314, 252-259.
44. Holinski, S., Claus, B., Alaaraj, N., Dohmen, P. M., Kirilova, K., Neumann, K., Uebelhack, R., and Konertz, W. (2008). Cerebroprotective effect of piracetam in patients undergoing coronary bypass surgery. Med. Sci. Monitor 14, I53-I57.
45. Hu, M., Schurdak, M. E., Puttfarcken, P. S., El Kouhen, R., Gopalakrishnan, M., and Li, J. H. (2007). High content screen microscopy analysis of Ap(1-42)-induced neurite outgrowth reduction in rat primary cortical neurons: neuroprotective effects of alpha 7 neuronal nicotinic acetylcholine receptor ligands. Brain Res. 1151, 227-235.
46. Ikeda, A., Shibasaki, H., Tashiro, K., Mizuno, Y., Kimura, J., Kohara, N., Kashiwagi, W., Ichikawa, H., Sakuragi, A., and Urano, Y. (1996). Clinical trial of piracetam in patients with myoclonus: nationwide multiinstitution study in Japan. Mov. Disord. 11, 691-700.
47. Israel, L., Melac, M., Milinkevitch, D., and Dubos, G. (1994). Drug therapy and memory training programs: a double-blind randomized trial of general practice patients with age-associated memory impairment. Int. Psychogeriatr. 6, 155-170.
48. Jha, N., Jurma, O., Lalli, G., Liu, Y., Pettus, E. H., Greenamyre, J. T., Liu, R. M., Forman, H. J., and Andersen, J. K. (2000). Glutathione depletion in PC12 results in selective inhibition of mitochondrial complex I activity - iImplications for Parkinson's disease. J. Biol. Chem. 275, 26096-26101.
49. Kahlert, S., Zundorf, G., and Reiser, G. (2008). Detection of de- and hyperpolarization of mitochondria of cultured astrocytes and neurons by the cationic fluorescent dye rhodamine 123. J. Neurosci. Methods 171, 87-92.
50. Karacostas, D., Doskas, T., Artemis, N., Vadicolias, K., and Milonas, I. (1999). Beneficial effect of piracetam monotherapy on post-ischaemic palatal myoclonus. J. Int. Med. Res. 27, 201-205.
51. Keil, U., Bonert, A., Marques, C. A., Scherping, I., Weyermann, J., Strosznajder, J. B., Muller-Spahn, F., Haass, C., Czech, C., Pradier, L., Muller, W. E., and Eckert, A. (2004a). Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J. Biol. Chem. 279, 50310-50320.
52. Keil, U., Bonert, A., Marques, C. A., Strosznajder, J. B., Muller-Spahn, F., Muller, W. E., and Eckert, A. (2004b). Elevated nitric oxide production mediates beta-amyloid-induced mitochondria failure. Pol. J. Pharmacol. 56, 631-634.
53. Keil, U., Scherping, I., Hauptmann, S., Schuessel, K., Eckert, A., and Muller, W. E. (2006). Piracetam improves mitochondrial dysfunction following oxidative stress. Br. J. Pharmacol. 147, 199-208.
54. Kurz, C., Ungerer, I., Lipka, U., Kirr, S., Schütt, T., Eckert, A., Leuner, K., and Müller, W. E. (2010). The metabolic enhancer piracetam ameliorates ß-amyloid peptide induced impairment of mitochondrial function and neuritic outgrowth. Br. J. Pharmacol. 160, 246-257.
55. Lacor, P. N., Buniel, M. C., Furlow, P. W., Clemente, A. S., Velasco, P. T., Wood, M., Viola, K. L., and Klein, W. L. (2007). Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 27, 796-807.
56. Lee, D. W., Huh, Y. S., and Kim, K. W. (2009). Evidence-based treatment of Alzheimer's disease. J. Korean Am. Med. Assoc. 52, 417-425.
57. Lemere, C. A., Beierschmitt, A., Iglesias, M., Spooner, E. T., Bloom, J. K., Leverone J. F., Zheng J. B., Seabrook T. J., Louard D., Li D., Selkoe D. J., Palmour R. M., and Ervin F. R. (2004). Alzheimer's disease A beta vaccine reduces central nervous system A beta levels in a non-human primate, the Caribbean Vervet. Am. J. Pathol. 165, 283-297.
58. Leuner, K., Hauptmann, S., Abdel-Kader, R., Scherping, I., Keil, U., Strosznajder, J. B., Eckert, A., and Muller, W. E. (2007). Mitochondrial dysfunction: the first domino in brain aging and Alzheimer's disease? Antioxid. Redox Signal 9, 1659-1675.
59. Malik, R., Sangwan, A., Saihgal, R., Jindal, D. P., and Piplani, P. (2007). Towards better brain management: nootropics. Curr. Med. Chem. 14, 123-131.
60. Mattson, M. P. (2000). Apoptosis in neurodegenerative disorders. Nat. Rev. Mol. Cell Biol. 1, 120-129.
61. Mattson, M. P. (2007). Mitochondrial regulation of neuronal plasticity. Neurochem. Res. 32, 707-715.
62. Mattson, M. P., Gleichmann, M., and Cheng, A. (2008). Mitochondria in neuroplasticity and neurological disorders. Neuron 60, 748-766.
63. Mattson, M. P., and Magnus, T. (2006). Ageing and neuronal vulnerability. Nat. Rev. Neurosci. 7, 278-294.
64. Moreira, P. I., Santos, M. S., and Oliveira, C. R. (2007). Alzheimer's disease: a lesson from mitochondrial dysfunction. Antioxid. Redox Signal 9, 1621-1630.
65. Müller, W. E., Eckert, A., Kurz, C., Eckert, G. P., and Leuner, K. (2010). Mitochondrial dysfunction: common final pathway in brain aging and Alzheimer's disease - therapeutic aspects. Mol. Neurobiol. 41, 159-171.
66. Muller, W. E., Eckert, G. P., and Eckert, A. (1999). Piracetam: novelty in a unique mode of action. Pharmacopsychiatry 32, 2-9.
67. Müller, W. E., Hartmann, H., Koch, S., Scheuer, K., and Stoll, S. (1994). Neurotransmission in aging - therapeutic aspects. Int. Acad. Biomed. Drug Res. 7, 166-173.
68. Muller, W. E., Koch, S., Scheuer, K., Rostock, A., and Bartsch, R. (1997). Effects of piracetam on membrane fluidity in the aged mouse, rat, and human brain. Biochem. Pharmacol. 53, 135-140.
69. Munch, G., Schinzel, R., Loske, C., Wong, A., Durany, N., Li, J. J., Vlassara, H., Smith, M. A., Perry, G., and Riederer, P. (1998). Alzheimer's disease - synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts. J. Neural Transm. 105, 439-461.
70. Muriel, P., and Perez-Rojas, J. M. (2003). Nitric oxide inhibits mitochondrial monoamine oxidase activity and decreases outer mitochondria membrane fluidity. Comp. Biochem. Physiol. C Comp. Pharmacol. Toxicol. 136, 191-197.
71. Onyango, I. G., Lu, J. H., Rodova, M., Lezi, E., Crafter, A. B., and Swerdlow, R. H. (2010). Regulation of neuron mitochondrial biogenesis and relevance to brain health. Biochim. Biophys. Acta 1802, 228-234.
72. Oosterveld, W. J. (1999). The effectiveness of piracetam in vertigo. Pharmacopsychiatry 32, 54-59.
73. Peuvot, J., Schanck, A., Deleers, M., and Brasseur, R. (1995). Piracetam-induced changes to membrane physical-properties - a combined approach by P-31 nuclear-magnetic-resonance and conformational-analysis. Biochem. Pharmacol. 50, 1129-1134.
74. Querfurth, H. W., and LaFerla, F. M. (2010). Alzheimer's disease. N. Engl. J. Med. 362, 329-344.
75. Reddy, P. H., and Beal, M. F. (2008). Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends. Mol. Med. 14, 45-53.
76. Rhein, V., Song, X. M., Wiesner, A., Ittner, L. M., Baysang, G., Meier, F., Ozmen, L., Bluethmann, H., Drose, S., Brandt, U., Savaskan, E., Czech, C., Gotz, J., and Eckert, A. (2009). Amyloid-beta and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc. Natl. Acad. Sci. U.S.A. 106, 20057-20062.
77. Ricchelli, F., Gobbo, S., Moreno, G., and Salet, C. (1999). Changes of the fluidity of mitochondrial membranes induced by the permeability transition. Biochemistry 38, 9295-9300.
78. Rosenhall, U., Deberdt, W., Friberg, U., Kerr, A., and Oosterveld, W. (1996). Piracetam in patients with chronic vertigo - results of a double-blind, placebo-controlled study. Clin. Drug Investig. 11, 251-260.
79. Saletu, B., Hitzenberger, G., Grunberger, J., Anderer, P., Zyhlarz, G., Linzmayer, L., and Rameis, H. (1995). Double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic studies with 2 new formulations of piracetam (infusion and syrup) under hypoxia in man. Int. J. Clin. Pharmacol. Ther. 33, 249-262.
80. Sastre, J., Lloret, A., Borras, C., Pereda, J., Garcia-Sala, D., Droy-Lefaix, M. T., Pallardo, F. V., and Vina, J. (2002). Ginkgo biloba extract EGb 761 protects against mitochondrial aging in the brain and in the liver. Cell. Mol. Biol. 48, 685-692.
81. Sastre, J., Pallardo, F. V., de la Asuncion, J. G., and Vina, J. (2000). Mitochondria, oxidative stress and aging. Free Radic. Res. 32, 189-198.
82. Scarmeas, N., Luchsinger, J. A., Mayeux, R., and Stern, Y. (2007). Mediterranean diet and Alzheimer disease mortality. Neurology 69, 1084-1093.
83. Scarmeas, N., Stern, Y., Mayeux, R., and Luchsinger, J. A. (2006). Mediterranean diet, Alzheimer disease, and vascular mediation. Arch. Neurol. 63, E1-E9.
84. Schaffer, S., Eckert, G. P., Schmitt-Schillig, S., and Muller, W. E. (2006). Plant foods and brain aging: a critical appraisal. Forum Nutr. 59, 86-115.
85. Scheuer, K., Rostock, A., Bartsch, R., and Muller, W. E. (1999). Piracetam improves cognitive performance by restoring neurochemical deficits of the aged rat brain. Pharmacopsychiatry 32, 10-16.
86. Schmitt-Schillig, S., Schaffer, S., Weber, C. C., Eckert, G. P., and Muller, W. E. (2005). Flavonoids and the aging brain. J. Physiol. Pharmacol. 56(Suppl. 1), 23-36.
87. Schuessel, K., Frey, C., Jourdan, C., Keil, U., Weber, C. C., Muller-Spahn, F., Muller, W. E., and Eckert, A. (2006). Aging sensitizes toward ROS formation and lipid peroxidation in PS1M146L transgenic mice. Free Radic. Biol. Med. 40, 850-862.
88. Selkoe, D. J. (2002). Alzheimer's disease is a synaptic failure. Science 298, 789-791.
89. Selkoe, D. J. (2008). Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav. Brain Res. 192, 106-113.
90. Stoll, L., Schubert, T., and Muller, W. E. (1992). Age-related deficits of central muscarinic cholinergic receptor function in the mouse - partial restoration by chronic piracetam treatment. Neurobiol. Aging 13, 39-44.
91. Szalma, I., Kiss, A., Kardos, L., Horvath, G., Nyitrai, E., Tordai, Z., and Csiba, L. (2006). Piracetam prevents cognitive decline in coronary artery bypass: A randomized trial versus placebo. Ann. Thorac. Surg. 82, 1430-1435.
92. Toupet, M. (2001). Management of vertigo and impaired-balance syndromes in the ederly. Presse Med. 30, 1273-1274.
93. Uebelhack, R., Vohs, K., Zytowski, M., Schewe, H. J., Koch, C., and Konertz, W. (2003). Effect of piracetam on cognitive performance in patients undergoing bypass surgery. Pharmacopsychiatry 36, 89-93.
94. Valzelli, L., Bernasconi, S., and Sala, A. (1980). Piracetam activity may differ according to the age of the recipient mouse. Int. Pharmacopsychiatry 15, 150-156.
95. Viana, G. S. B., Marinho, M. M. F., and Sousa, F. C. F. (1992). Effect of piracetam administration on 3H-N-methylscopolamine binding in cerebral-cortex of young and old rats. Life Sci. 50, 971-977.
96. Waegemans, T., Wilsher, C. R., Danniau, A., Ferris, S. H., Kurz, A., and Winblad, B. (2002). Clinical efficacy of piracetam in cognitive impairment: a meta-analysis. Dement. Geriatr. Cogn. Disord. 13, 217-224.
97. Waldbaum, S., and Patel, M. (2010). Mitochondria, oxidative stress, and temporal lobe epilepsy. Epilepsy Res. 88, 23-45.
98. Wang, X., Zhu, J., Xu, R., Yang, X., Wu, H., Lin, D., Ye, F., and Hu, L. (2010). Determination of piracetam in rat plasma by LC-MS/MS and its application to pharmacokinetics. Biomed. Chromatogr. doi: 10.1002/bmc.1414 [Epub ahead of print].
99. Wilsher, C. R. (1986). Effects of piracetam on developmental dyslexia. Int. J. Psychophysiol. 4, 29-39.
100. Wilsher, C. R., Bennett, D., Chase, C. H., Conners, C. K., Diianni, M., Feagans, L., Hanvik, L. J., Helfgott, E., Koplewicz, H., Overby, P., Reader, M. J., Rudel, R. G., and Tallal, P. (1987). Piracetam and dyslexia - effects on reading tests. J. Clin. Psychopharmacol. 7, 230-237.
101. Winblad, B. (2005). Piracetam: a review of pharmacological properties and clinical uses. CNS Drug Rev. 11, 169-182.
102. Wolters, A., and Benecke, R. (2009). Myoclonus. Aktuel. Neurol. 36, 71-81.
103. Xerri, C., and Zennou-Azogui, Y. (2003). Influence of the postlesion environment and chronic piracetam treatment on the organization of the somatotopic map in the rat primary somatosensory cortex after focal cortical injury. Neuroscience 118, 161-177.
104. Zhang, X., Liu, W., Niu, X., and An, L. (2010). Systemic administration of catalpol prevents D-galactose induced mitochondrial dysfunction in mice. Neurosci. Lett. 473, 224-228.